Studies & Publications

Through a pioneering partnership between Bioquantine's® (BQ) scientific innovators and EAVE Cosmetics, this biotechnology is being translated into a real-world revolution in luxury skin care. By combining deep regenerative science with elevated formulation design, EAVE is not only introducing Bioquantine to consumers—it's redefining what modern skin care can achieve. This collaboration marks the beginning of a new frontier: one where clinical-grade cellular repair becomes part of everyday skin care rituals.

Bioquantine is not a traditional skin care ingredient. It is a patented extract composed of a proprietary blend of intra- and extra-cellular biomolecules released from Xenopus laevis oocytes. The process begins with proprietary electromagnetic stimulation, which primes the cells for the next stage. Following this, electroporation is applied, using electrical pulses to temporarily open cellular pores, enabling the oocytes to release powerful signaling molecules. In the final step, the bio-photon correction process ensures the effective release of these key bio-signals, including:

• MicroRNAs (miRNAs): Regulate post-transcriptional gene expression
• Pluripotency-Related Proteins: Such as Sox2, Oct4 and Nanog, crucial for maintaining stem cell pluripotency
• Molecular Factors: Associated with embryonic development and cellular reprogramming

These bio-signals are preserved and formulated to interact with human skin cells, delivering a complex biological message that promotes regeneration, renewal and resilience.

Aging skin is not merely the result of external damage; it is a biological process marked by cellular senescence, inflammation and a decline in regenerative communication. Traditional anti-aging ingredients target surface symptoms, whereas Bioquantine addresses the root cause: the breakdown of cellular programming. In controlled in vitro studies, Bioquantine has shown the ability to reprogram human somatic cells, including:

• Bone marrow stromal cells 
• CD4+ T lymphocytes
• Pre-adipocytes
• HeLa cancer cells

These cells, upon exposure to Bioquantine, began expressing key pluripotency markers like TRA- 1-60 and Nanog, demonstrating a shift toward a more youthful, regenerative phenotype. Some cells exhibited spontaneous colony formation and even neural lineage transdifferentiation under the appropriate culture conditions. This regenerative behavior is foundational to Bioquantine’s action in the skin, where similar signaling pathways govern dermal repair, extracellular matrix synthesis, and cellular turnover.

Bioquantine is currently being applied in advanced cosmetic protocols, most notably in:

• BioActivated PRP (Platelet-Rich Plasma + BQ)
• Topical regenerative creams and serums
• Adjunct oral nutraceutical supplementation

A multi-phase dermatological protocol combining topical Bioquantine, oral Lycopersicon esculentum extract and PRP-based therapy resulted in:

• Improved tone, elasticity and hydration in participants
• Reduction of wrinkles and sun-damage pigmentation
• Faster recovery and healing post-treatment (e.g., microneedling)
• Increased patient-reported satisfaction

In an expanded clinical review of aesthetic treatment outcomes, participants using Bioquantine-enriched PRP protocols consistently reported:

• Visible reduction in dynamic and static wrinkles as early as two weeks post-treatment
• Enhanced healing response post-laser resurfacing, with less inflammation and faster recovery
• Improved skin density and lift, especially in lower-face and under-eye zones
• Restored moisture barrier, leading to longer-lasting hydration and reduced trans-epidermal water loss (TEWL)

Before-and-after dermoscopic analysis and standardized skin scoring (e.g., Fitzpatrick Wrinkle Score and Global Aesthetic Improvement Scale) confirmed significant clinical improvements compared to PRP alone. These outcomes further solidify Bioquantine’s role in elevating conventional cosmetic interventions to regenerative therapy status.

.

BQ downregulates inflammatory enzymes such as COX-2 and iNOS, commonly elevated in aged or photodamaged skin. This results in reduced redness, irritation and oxidative stress—all key contributors to aging.

Bioquantine stimulates fibroblasts and dermal matrix regeneration, encouraging the production of:

• Collagen types I and III
• Elastin
• Hyaluronic acid

This enhances skin firmness, volume and moisture retention.

Through miRNA delivery, Bioquantine supports:

• DNA methylation balance
• Histone remodeling
• Gene reactivation associated with cellular repair

This positions BQ not only as an aesthetic agent, but as a true epigenetic modulator.

Bioquantine is produced under pharmaceutical-grade protocols with no synthetic additives, hormones or genetic modification. The electroporated oocyte extract is sterilized, filtered and tested for:

• Endotoxins
• Pathogens
• Heavy metals
• Allergens

The final material used in skin care is biocompatible and suitable for topical and injection-based delivery systems.

What distinguishes Bioquantine from all other cosmetic actives is its origin and function:

• It does not mimic nature—it is nature, activated.
• It does not hydrate skin—it restores skin behavior.
• It does not treat symptoms—it instructs repair.

No other skin care ingredient today offers this level of cellular influence, nor the science to support multi-layered tissue rejuvenation. Bioquantine operates at the intersection of biology and beauty, defining a new category: regenerative cosmeceuticals.

Bioquantine is not a cosmetic innovation—it is a biological awakening. With its foundation in cellular reprogramming, epigenetic modulation and regenerative instruction, it has the potential to dramatically shift how we approach aging, skin health and longevity.

As an exclusive technology used by EAVE Cosmetics, Bioquantine is ushering in a new era where skin doesn’t just appear youthful—it becomes youthful again.

References:

1. Paylian, S., et al. (2015). Reprogramming with Xenopus laevis Oocyte Extracts. BAOJ Cancer Res Ther, 1(2).

2. Paylian, S., et al. (2016). Therapeutic Use of Bioquantine in Degenerative Conditions. Clinical Trials, 1(2).

3. Bioquantine In Vitro Report, Bioquark Inc. Internal Data, 2023.

4. Bioquantine Skincare Clinical Use Whitepaper, Regenerage International, 2020.